newsfilter
← Latest News
GlobeNewswire·

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European